

June 11, 2007

***IN THE CLAIMS***

Please replace all prior versions and listing of claims in the application with this listing of claims.

***Complete listing of claims:***

- 1-48. (Cancelled).
- 49. (New) A solid oral pharmaceutical composition comprising:
  - (a) non-enteric coated acid labile proton pump inhibitor in an amount of about 2 to about 100 mg; and
  - (b) about 0.1 mEq to about 2.5 mEq of buffering agent per mg of the proton pump inhibitor;

wherein the buffering agent is present in the solid oral pharmaceutical composition in an amount sufficient to permit absorption of a therapeutically effective amount of the proton pump inhibitor after oral administration to a subject.

50. (New) The composition of claim 49, wherein upon administration of the solid oral pharmaceutical composition, a therapeutic amount of the proton pump inhibitor is absorbed in about 10 to about 12 minutes.

51. (New) The solid oral pharmaceutical composition of claim 49, wherein the proton pump inhibitor is a substituted benzimidazole.

52. (New) The solid oral pharmaceutical composition of claim 49, wherein the substituted benzimidazole is omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dantoprazole, perprazole, habeprazole, or a derivative, enantiomer, isomer, free base or salt thereof.

53. (New) The solid oral pharmaceutical composition of claim 49, wherein the proton pump inhibitor is omeprazole.

54. (New) The solid oral pharmaceutical composition of claim 49, wherein the proton pump inhibitor is present in an amount of about 20 mg.

55. (New) The solid oral pharmaceutical composition of claim 53, wherein the proton pump inhibitor is present in an amount of about 40 mg.

56. (New) The solid oral pharmaceutical composition of claim 49, wherein said solid oral pharmaceutical composition is in a dosage form selected from the group consisting of a tablet, a capsule, an effervescent powder, pellets and granules.

57. (New) The solid oral pharmaceutical composition of claim 49, wherein the dosage form is a capsule.

58. (New) The solid oral pharmaceutical composition of claim 49, wherein the dosage form is a tablet.

59. (New) The solid oral pharmaceutical composition of claim 49, wherein the buffering agent comprises about 0.375 mEq to about 0.75 mEq of buffering agent per mg of the proton pump inhibitor.

60. (New) The solid oral pharmaceutical composition of claim 49, wherein the buffering agent is sodium bicarbonate.

61. (New) The solid oral pharmaceutical composition of claim 49, wherein the proton pump inhibitor is micronized.

62. (New) A method of treating a gastrointestinal condition comprising administering to a patient a solid oral pharmaceutical composition comprising:

- (a) non-enteric coated acid labile proton pump inhibitor in an amount of about 2 to about 100 mg; and
- (b) about 0.1 mEq to about 2.5 mEq of buffering agent per mg of the proton pump inhibitor;

wherein the buffering agent is present in the solid oral pharmaceutical composition in an amount sufficient to permit absorption of a therapeutically effective amount of the proton pump inhibitor after oral administration to a subject

63. (New) The method of claim 63, wherein upon administration of the solid oral pharmaceutical composition, a therapeutic amount of the proton pump inhibitor is absorbed in about 10 to about 12 minutes.

64. (New) The method of claim 63, wherein the proton pump inhibitor is a substituted benzimidazole.

65. (New) The method of claim 63, wherein the substituted benzimidazole is omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dextroprazole, perprazole, habeprazole, or a derivative, enantiomer, isomer, free base or salt thereof.

- 66. (New) The method of claim 63, wherein the proton pump inhibitor is omeprazole.
- 67. (New) The method of claim 63, wherein the proton pump inhibitor is present in an amount of about 20 mg.
- 68. (New) The method of claim 63, wherein the proton pump inhibitor is present in an amount of about 40 mg.
- 69. (New) The method of claim 63, wherein said solid oral pharmaceutical composition is in a dosage form selected from the group consisting of a tablet, a capsule, an effervescent powder, pellets and granules.
- 70. (New) The method of claim 63, wherein the dosage form is a capsule.
- 71. (New) The method of claim 63, wherein the dosage form is a tablet.
- 72. (New) The method of claim 63, wherein the buffering agent comprises about 0.375 mEq to about 0.75 mEq of buffering agent per mg of the proton pump inhibitor.
- 73. (New) The method of claim 63, wherein the buffering agent is sodium bicarbonate.
- 74. (New) The method of claim 63, wherein the proton pump inhibitor is micronized.